292 related articles for article (PubMed ID: 25698905)
1. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.
Wells PS; Gebel M; Prins MH; Davidson BL; Lensing AW
Thromb J; 2014; 12():26. PubMed ID: 25698905
[TBL] [Abstract][Full Text] [Related]
2. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
3. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
Bauersachs RM; Lensing AW; Prins MH; Kubitza D; Pap ÁF; Decousus H; Beyer-Westendorf J; Prandoni P
Thromb J; 2014; 12():25. PubMed ID: 25750589
[TBL] [Abstract][Full Text] [Related]
5. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
Prins MH; Lensing AW; Bauersachs R; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Raskob GE; Berkowitz SD; Wells PS;
Thromb J; 2013 Sep; 11(1):21. PubMed ID: 24053656
[TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
[TBL] [Abstract][Full Text] [Related]
7. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.
Wang Y; Wang C; Chen Z; Zhang J; Liu Z; Jin B; Ying K; Liu C; Shao Y; Jing Z; Meng IL; Prins MH; Pap AF; Müller K; Lensing AW;
Thromb J; 2013 Dec; 11(1):25. PubMed ID: 24341332
[TBL] [Abstract][Full Text] [Related]
10. Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.
Yamada N; Hirayama A; Maeda H; Sakagami S; Shikata H; Prins MH; Lensing AW; Kato M; Onuma J; Miyamoto Y; Iekushi K; Kajikawa M
Thromb J; 2015; 13():2. PubMed ID: 25717286
[TBL] [Abstract][Full Text] [Related]
11. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
14. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Davidson BL; Verheijen S; Lensing AW; Gebel M; Brighton TA; Lyons RM; Rehm J; Prins MH
JAMA Intern Med; 2014 Jun; 174(6):947-53. PubMed ID: 24733305
[TBL] [Abstract][Full Text] [Related]
15. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Martinelli I; Lensing AW; Middeldorp S; Levi M; Beyer-Westendorf J; van Bellen B; Bounameaux H; Brighton TA; Cohen AT; Trajanovic M; Gebel M; Lam P; Wells PS; Prins MH
Blood; 2016 Mar; 127(11):1417-25. PubMed ID: 26696010
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
17. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
18. Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Wells PS; Lensing AWA; Haskell L; Levitan B; Laliberté F; Durkin M; Ashton V; Xiao Y; Crivera C; Lejeune D; Schein J; Lefebvre P
J Med Econ; 2018 Jun; 21(6):587-594. PubMed ID: 29469638
[TBL] [Abstract][Full Text] [Related]
19. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
Cheung YW; Middeldorp S; Prins MH; Pap AF; Lensing AW; Ten Cate-Hoek AJ; Villalta S; Milan M; Beyer-Westendorf J; Verhamme P; Bauersachs RM; Prandoni P;
Thromb Haemost; 2016 Sep; 116(4):733-8. PubMed ID: 27583311
[TBL] [Abstract][Full Text] [Related]
20. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
